The test is geared toward personalized immunosuppresion for solid organ transplant patients.
“Genomic analysis of blood can reveal early signs of rejection in transplanted kidneys,” said Mark Stegall, MD, a Mayo-affiliated principal investigator in the research project. “The potential clinical utility is to be able to monitor for rejection more frequently than is possible with surveillance biopsies and to individualize immunosuppresion in transplant recipients.”
In addition to research, the collaboration includes an assessment of Transplant Genomics’ TruGraf test for rental transplant monitoring, an undisclosed Mayo Clinic investment in TGI and co-development of new tests and technologies for other transplant targets.
More articles on genomics:
The ethics of genomics: 4 explorations
How the Energy Department’s supercomputers are aiding the Cancer Moonshot
Genomic sequencing can help determine end of a TB outbreak
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
